56 related articles for article (PubMed ID: 20362521)
1. [Secondary hyperparathyroidism in advanced prostate cancer].
Quirosa Flores S; Varsavsky M; Valle Díaz De La Guardia F; Miján Ortiz JL; Muñoz Torres M; Raya Alvarez E; Zuluaga Gómez A
Endocrinol Nutr; 2010 Mar; 57(3):100-4. PubMed ID: 20362521
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
Schwartz GG
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
[TBL] [Abstract][Full Text] [Related]
3. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer.
Murray RM; Grill V; Crinis N; Ho PW; Davison J; Pitt P
J Clin Endocrinol Metab; 2001 Sep; 86(9):4133-8. PubMed ID: 11549639
[TBL] [Abstract][Full Text] [Related]
4. Increases in parathyroid hormone (PTH) after gastric bypass surgery appear to be of a secondary nature.
Jin J; Robinson AV; Hallowell PT; Jasper JJ; Stellato TA; Wilhem SM
Surgery; 2007 Dec; 142(6):914-20; discussion 914-20. PubMed ID: 18063076
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
[TBL] [Abstract][Full Text] [Related]
7. Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets.
Savio RM; Gosnell JE; Posen S; Reeve TS; Delbridge LW
Arch Surg; 2004 Feb; 139(2):218-22. PubMed ID: 14769584
[TBL] [Abstract][Full Text] [Related]
8. Secondary hyperparathyroidism in patients on maintenance hemodialysis.
Hida M
Tokai J Exp Clin Med; 1982 Nov; 7(6):665-70. PubMed ID: 7184198
[TBL] [Abstract][Full Text] [Related]
9. Advanced but not localized prostate cancer is associated with increased oxidative stress.
Yossepowitch O; Pinchuk I; Gur U; Neumann A; Lichtenberg D; Baniel J
J Urol; 2007 Oct; 178(4 Pt 1):1238-43; discussion 1243-4. PubMed ID: 17698111
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
11. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
12. Hypocalcemia with osteoblastic metastases in patient with prostate carcinoma. A cause of secondary hyperparathyroidism.
Smallridge RC; Wray HL; Schaaf M
Am J Med; 1981 Jul; 71(1):184-8. PubMed ID: 7246580
[TBL] [Abstract][Full Text] [Related]
13. Role of estrogen deficiency in pathogenesis of secondary hyperparathyroidism and increased bone resorption in elderly women.
McKane WR; Khosla S; Risteli J; Robins SP; Muhs JM; Riggs BL
Proc Assoc Am Physicians; 1997 Mar; 109(2):174-80. PubMed ID: 9069586
[TBL] [Abstract][Full Text] [Related]
14. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
[TBL] [Abstract][Full Text] [Related]
15. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
Ito H; Kinugasa E
Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
[TBL] [Abstract][Full Text] [Related]
18. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
20. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
